Literature DB >> 11895622

Management of cutaneous drug reactions.

K S Babu1, Geeta Belgi.   

Abstract

Drugs are potent chemicals that often have effects in the body beyond the desired action. These effects may range from mild and expected side effects to dramatic and life-threatening anaphylaxis. Adverse drug reactions account for between 2% and 6% of hospital admissions and may prevent administration of otherwise effective therapeutic agents. Cutaneous and mucocutaneous eruptions are the most common adverse reactions to oral or parenteral drug therapy, and the spectrum ranges from transitory exanthematous rash to the potentially fatal toxic epidermal necrolysis. Different mechanisms, including both immunologic and nonimmunologic, are responsible for cutaneous adverse drug reaction. The treatment of cutaneous drug eruptions essentially rests on accurate history, a thorough physical examination, discontinuation of the offending drug, and supportive care. The management of a cutaneous drug eruption is very much individualized, based on the clinical setting. This review aims to provide a general approach to the patient with a presumed cutaneous drug reaction.

Entities:  

Mesh:

Year:  2002        PMID: 11895622     DOI: 10.1007/s11882-002-0034-x

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  59 in total

Review 1.  Idiosyncratic drug reactions: the reactive metabolite syndromes.

Authors:  S R Knowles; J Uetrecht; N H Shear
Journal:  Lancet       Date:  2000-11-04       Impact factor: 79.321

Review 2.  Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection.

Authors:  H M Heller
Journal:  Clin Dermatol       Date:  2000 Jul-Aug       Impact factor: 3.541

Review 3.  Genetic susceptibility to adverse drug reactions.

Authors:  M Pirmohamed; B K Park
Journal:  Trends Pharmacol Sci       Date:  2001-06       Impact factor: 14.819

4.  Patch testing with carbamazepine: reinduction of an exfoliative dermatitis.

Authors:  L Vaillant; I Camenen; G Lorette
Journal:  Arch Dermatol       Date:  1989-02

5.  Intestinal involvement in drug-induced toxic epidermal necrolysis.

Authors:  O Chosidow; J C Delchier; M T Chaumette; J Wechsler; P Wolkenstein; I Bourgault; J C Roujeau; J Revuz
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

6.  Patch test diagnosis of exfoliative dermatitis due to carbamazepine.

Authors:  J G Camarasa
Journal:  Contact Dermatitis       Date:  1985-01       Impact factor: 6.600

Review 7.  Medication-related adverse reactions and the elderly: a literature review.

Authors:  P A Atkin; G M Shenfield
Journal:  Adverse Drug React Toxicol Rev       Date:  1995

8.  Toxic epidermal necrolysis. A step forward in treatment.

Authors:  D M Heimbach; L H Engrav; J A Marvin; T J Harnar; B J Grube
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

9.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  Nail and mucocutaneous hyperpigmentation with azidothymidine therapy.

Authors:  R G Greenberg; T G Berger
Journal:  J Am Acad Dermatol       Date:  1990-02       Impact factor: 11.527

View more
  2 in total

1.  An observational study of cutaneous adverse drug reactions in a teaching hospital.

Authors:  Deepti Chopra; Vibha Sharma; Rohan Kapoor; Shridhar Dwivedi
Journal:  Int J Clin Pharm       Date:  2015-08-04

2.  Clinical features and etiology of adult patients with Fever and rash.

Authors:  Fehmi Tabak; Aysan Murtezaoglu; Omur Tabak; Resat Ozaras; Bilgul Mete; Zekayi Kutlubay; Ali Mert; Recep Ozturk
Journal:  Ann Dermatol       Date:  2012-11-08       Impact factor: 1.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.